Aerovate Therapeutics Inc

NASDAQ AVTE

Data sourced from iex and EODHD
Download Data

Aerovate Therapeutics Inc Enterprise Value (EV) on June 03, 2024

Aerovate Therapeutics Inc Enterprise Value (EV) is NA on June 03, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.
  • Aerovate Therapeutics Inc 52-week high Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
  • Aerovate Therapeutics Inc 52-week low Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
  • Aerovate Therapeutics Inc average Enterprise Value (EV) for the last 52 weeks is NA.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email